Dr Reddy’s gets US FDA approval for rituximab biosimilar; Fresenius Kabi to commercialise product
Dr Reddy’s Laboratories on Saturday (August 1) said it has received approval from the US Food and Drug Administration (FDA) for its rituximab biosimilar, a biosimilar version of Rituxan (rituximab), for the US market. The approval strengthens the Hyderabad-based drugmaker’s biosimilars portfolio and marks another step in expanding its presence in the US pharmaceutical market….
